CN1418100A - 控制视野丧失的具有5－ht活性的化合物 - Google Patents

控制视野丧失的具有5－ht活性的化合物 Download PDF

Info

Publication number
CN1418100A
CN1418100A CN01806620A CN01806620A CN1418100A CN 1418100 A CN1418100 A CN 1418100A CN 01806620 A CN01806620 A CN 01806620A CN 01806620 A CN01806620 A CN 01806620A CN 1418100 A CN1418100 A CN 1418100A
Authority
CN
China
Prior art keywords
compounds
compound
group
glaucoma
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01806620A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·小科利尔
M·R·赫尔伯格
T·R·迪安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of CN1418100A publication Critical patent/CN1418100A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
CN01806620A 2000-03-17 2001-02-23 控制视野丧失的具有5－ht活性的化合物 Pending CN1418100A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
US60/190,279 2000-03-17

Publications (1)

Publication Number Publication Date
CN1418100A true CN1418100A (zh) 2003-05-14

Family

ID=22700682

Family Applications (2)

Application Number Title Priority Date Filing Date
CN01806620A Pending CN1418100A (zh) 2000-03-17 2001-02-23 控制视野丧失的具有5－ht活性的化合物
CNB018067646A Expired - Fee Related CN1198605C (zh) 2000-03-17 2001-02-23 用于治疗视网膜外层疾病的具有5－ht1a活性的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018067646A Expired - Fee Related CN1198605C (zh) 2000-03-17 2001-02-23 用于治疗视网膜外层疾病的具有5－ht1a活性的化合物

Country Status (18)

Country Link
EP (3) EP1263434A1 (enExample)
JP (5) JP2003527423A (enExample)
KR (3) KR20030016239A (enExample)
CN (2) CN1418100A (enExample)
AR (1) AR028258A1 (enExample)
AT (1) ATE247507T1 (enExample)
AU (5) AU2001238552A1 (enExample)
BR (3) BR0109193A (enExample)
CA (3) CA2400637A1 (enExample)
DE (1) DE60100625T2 (enExample)
DK (1) DK1263504T3 (enExample)
ES (1) ES2204848T3 (enExample)
MX (3) MXPA02009071A (enExample)
PL (1) PL203709B1 (enExample)
PT (1) PT1263504E (enExample)
TW (1) TWI268777B (enExample)
WO (3) WO2001070223A1 (enExample)
ZA (1) ZA200206350B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
EP1263434A1 (en) * 2000-03-17 2002-12-11 Alcon, Inc Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
EP1581209A4 (en) 2002-12-13 2009-03-11 Alcon Inc NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
EP1617838A4 (en) * 2003-04-25 2011-07-06 Mitsubishi Tanabe Pharma Corp COMPOSITION FOR ORAL ADMINISTRATION WITH ALKYLENEDIOXYBENZOLE DERIVATIVES
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
JP7636796B2 (ja) 2019-02-27 2025-02-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
CA3239565A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
IL313499A (en) * 2021-12-23 2024-08-01 Cilcare Dev Derivatives of 4-phenyl-tetrahydropyridine for the treatment of hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
EP1263434A1 (en) * 2000-03-17 2002-12-11 Alcon, Inc Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma

Also Published As

Publication number Publication date
DE60100625D1 (de) 2003-09-25
AU2005202600B2 (en) 2008-07-31
DE60100625T2 (de) 2004-02-26
KR20020082885A (ko) 2002-10-31
PL203709B1 (pl) 2009-11-30
JP4789231B2 (ja) 2011-10-12
CA2400639C (en) 2011-08-16
CA2400639A1 (en) 2001-09-27
MXPA02009071A (es) 2003-05-23
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
WO2001070223A1 (en) 2001-09-27
TWI268777B (en) 2006-12-21
WO2001070230A3 (en) 2002-04-25
WO2001070222A3 (en) 2002-07-25
MXPA02009072A (es) 2003-03-12
CA2399985A1 (en) 2001-09-27
AR028258A1 (es) 2003-04-30
KR100749191B1 (ko) 2007-08-13
BR0109230A (pt) 2003-06-03
JP2003527423A (ja) 2003-09-16
WO2001070230A2 (en) 2001-09-27
KR20030009390A (ko) 2003-01-29
HK1051504A1 (en) 2003-08-08
KR20030016239A (ko) 2003-02-26
DK1263504T3 (da) 2003-12-08
CA2400637A1 (en) 2001-09-27
EP1263504A2 (en) 2002-12-11
AU4531001A (en) 2001-10-03
EP1267878A2 (en) 2003-01-02
JP2011037901A (ja) 2011-02-24
ES2204848T3 (es) 2004-05-01
EP1263504B1 (en) 2003-08-20
CN1418121A (zh) 2003-05-14
BR0109193A (pt) 2003-05-27
JP2003527427A (ja) 2003-09-16
PL358306A1 (en) 2004-08-09
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
EP1263434A1 (en) 2002-12-11
MXPA02009073A (es) 2003-03-12
AU2001239836A1 (en) 2001-10-03
PT1263504E (pt) 2003-12-31
JP2011153158A (ja) 2011-08-11
JP2003527422A (ja) 2003-09-16
WO2001070222A2 (en) 2001-09-27
ATE247507T1 (de) 2003-09-15
CN1198605C (zh) 2005-04-27
ZA200206350B (en) 2003-08-08

Similar Documents

Publication Publication Date Title
CN1418100A (zh) 控制视野丧失的具有5－ht活性的化合物
EP0686393B1 (en) Ophthalmic preparations containing sarpogrelate for reducing intraocular pressure
EP2156833A1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US20100168121A1 (en) Compounds with 5-ht1a activity useful for treating disorders of the outer retina
US20060111388A1 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
WO2004045644A1 (ja) Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
EP0672417A1 (en) Reduction of elevated intraocular pressure
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US20030119846A1 (en) Compounds with 5-ht activity useful for controlling visual field loss
US5308849A (en) Method of reducing elevated intraocular pressure
US20030114512A1 (en) Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
EP0728480A1 (en) Use of ifenprodil for treatment of elevated intraocular pressure
JPH10500130A (ja) テラゾシンを含有する緑内障治療用医薬組成物
EP1051973B1 (en) Optic papillary circulation improving agents
JPH07304663A (ja) 眼圧降下用点眼剤
HK1051504B (en) Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication